Nanologica Q1 2025: Initial take – largely as expected
16 april, 08:56
Redeye leaves its initial comments on Nanologica's Q1 report which came in largely as expected showing minor positive deviation on sales and a slight shortfall in EBITDA.
Ämnen i artikeln
Nanologica Q1 2025: Initial take – largely as expected
16 april, 08:56
Redeye leaves its initial comments on Nanologica's Q1 report which came in largely as expected showing minor positive deviation on sales and a slight shortfall in EBITDA.
Ämnen i artikeln
Analyser
Aktieråd
SBB
Inflationen
Analyser
Aktieråd
SBB
Inflationen
Marknadsöversikt
1 DAG %
Senast
1 mån
